Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL OTCMKTS:CYAN NASDAQ:OKYO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.07+1.9%$1.32$0.88▼$1.71$121.01M0.72365,376 shs255,076 shsCYANCyanotech$0.40+2.6%$0.41$0.21▼$0.57$2.88M0.15664 shs3,999 shsOKYOOKYO Pharma$1.55+4.0%$1.62$1.44▼$3.35$60.43M0.0247,387 shs54,950 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-2.78%-6.25%-21.35%-0.47%-27.59%CYANCyanotech-11.36%-11.36%-5.25%-13.04%-7.12%OKYOOKYO Pharma-3.25%-10.24%-9.70%-12.35%-28.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.07+1.9%$1.32$0.88▼$1.71$121.01M0.72365,376 shs255,076 shsCYANCyanotech$0.40+2.6%$0.41$0.21▼$0.57$2.88M0.15664 shs3,999 shsOKYOOKYO Pharma$1.55+4.0%$1.62$1.44▼$3.35$60.43M0.0247,387 shs54,950 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-2.78%-6.25%-21.35%-0.47%-27.59%CYANCyanotech-11.36%-11.36%-5.25%-13.04%-7.12%OKYOOKYO Pharma-3.25%-10.24%-9.70%-12.35%-28.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 2.33Hold$8.50694.39% UpsideCYANCyanotech 0.00N/AN/AN/AOKYOOKYO Pharma 2.40Hold$6.33308.60% UpsideCurrent Analyst Ratings BreakdownLatest PHE, CYAN, CRDL, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/ACYANCyanotech$24.22M0.12N/AN/A$1.23 per share0.33OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)CYANCyanotech-$3.20M-$0.25N/AN/AN/A-7.03%-20.62%-7.52%N/AOKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)Latest PHE, CYAN, CRDL, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACYANCyanotechN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol TherapeuticsN/A4.394.39CYANCyanotech0.121.000.30OKYOOKYO PharmaN/A0.58N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%CYANCyanotech24.40%OKYOOKYO Pharma2.97%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%CYANCyanotech34.40%OKYOOKYO Pharma40.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableCYANCyanotech957.39 million4.85 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionablePHE, CYAN, CRDL, and OKYO HeadlinesRecent News About These CompaniesOKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Consensus Rating of "Hold" by AnalystsMay 31, 2026 | americanbankingnews.comOKYO Pharma expands scientific advisory board with cornea expert - ICYMIMay 23, 2026 | proactiveinvestors.comWhat Makes OKYO Pharma (OKYO) a New Buy StockMay 20, 2026 | zacks.comOKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti AppointmentMay 19, 2026 | finance.yahoo.comOKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory BoardMay 19, 2026 | proactiveinvestors.comOKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhDMay 19, 2026 | globenewswire.comOKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in MayApril 29, 2026 | globenewswire.comOKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026April 7, 2026 | finance.yahoo.comOKYO Pharma advances clinical strategy with SAB meeting and ASCRS presentationApril 7, 2026 | proactiveinvestors.comOKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual MeetingApril 7, 2026 | globenewswire.comMost and least shorted healthcare stocks with up to $2B market cap in MarchApril 3, 2026 | msn.comOKYO reports improved quality of life outcomes with urcosimod in phase 2a NCP trialMarch 20, 2026 | ophthalmologytimes.comOOKYO Pharma Announces Chairman and Founder Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Director Acquires SharesMarch 19, 2026 | globenewswire.comOKYO Pharma Announces Chief Development Officer and Director Acquires SharesMarch 19, 2026 | globenewswire.comFTSE 100 Live: Stocks expected to slump as oil prices soar on Iran counterattacksMarch 19, 2026 | proactiveinvestors.comOKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trialMarch 18, 2026 | proactiveinvestors.comOKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal PainMarch 18, 2026 | globenewswire.comNasdaq, Dow Jones start the week lower as Trump resets tariffsFebruary 23, 2026 | finance.yahoo.comOKYO Pharma to present first-in-human urcosimod data at ARVO 2026February 23, 2026 | proactiveinvestors.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Palomar’s High-Risk Insurance Strategy Is Paying Off BigBy Peter Frank | May 29, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026Allstate’s Comeback Is Turning Into a Profit MachineBy Peter Frank | June 8, 2026PHE, CYAN, CRDL, and OKYO Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.07 +0.02 (+1.90%) Closing price 04:00 PM EasternExtended Trading$1.08 +0.01 (+1.31%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Cyanotech OTCMKTS:CYAN$0.40 +0.01 (+2.56%) As of 10:46 AM EasternCyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.OKYO Pharma NASDAQ:OKYO$1.55 +0.06 (+4.03%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.01 (+0.65%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
